Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.

abstract：:Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

journal_title：Antiviral therapy

authors： Forton D,Weissenborn K,Bondin M,Cacoub P

更新日期：2018-01-01 00:00:00

abstract：:Active pharmaceutical ingredients (APIs) are the molecular entities that exert the therapeutic effects of medicines. This article provides an overview of the major APIs that are entered into antiretroviral therapy (ART), outlines how APIs are manufactured, and examines the regulatory and cost frameworks of manufacturi...

journal_title：Antiviral therapy

authors： Fortunak JM,de Souza RO,Kulkarni AA,King CL,Ellison T,Miranda LS

更新日期：2014-01-01 00:00:00

abstract：:The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

journal_title：Antiviral therapy

authors： Kosmiski LA,Miller HL,Klemm DJ

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment. METHODS:Serum HBsAg was quantified by ADVIA Centaur in 63 patients with HBeAg-negative chronic hepatitis B (CHBe-). A total of 42 had received interferon-alpha2b (IFN-alpha2b...

journal_title：Antiviral therapy

authors： Manesis EK,Hadziyannis ES,Angelopoulou OP,Hadziyannis SJ

更新日期：2007-01-01 00:00:00

abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

journal_title：Antiviral therapy

authors： Calle Serrano B,Manns MP

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...

journal_title：Antiviral therapy

authors： Tural C,Galeras JA,Planas R,Coll S,Sirera G,Giménez D,Salas A,Rey-Joly C,Cirera I,Márquez C,Tor J,Videla S,García-Retortillo M,Clotet B,Solà R

更新日期：2008-01-01 00:00:00

abstract：:Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

journal_title：Antiviral therapy

authors： Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

更新日期：2000-09-01 00:00:00

abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...

journal_title：Antiviral therapy

authors： Huang YW,Takahashi S,Tsuge M,Chen CL,Wang TC,Abe H,Hu JT,Chen DS,Yang SS,Chayama K,Kao JH

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

journal_title：Antiviral therapy

authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...

journal_title：Antiviral therapy

authors： Ruiz-Camps I,Len O,de la Cámara R,Gurguí M,Martino R,Jarque I,Barrenetxea C,Díaz de Heredia C,Batlle M,Rovira M,de la Torre J,Torres A,Aguilar M,Espigado I,Martín-Dávila P,Bou G,Borrell N,Aguado JM,Pahissa A,Spanish

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

journal_title：Antiviral therapy

authors： Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...

journal_title：Antiviral therapy

authors： Mutagoma M,Ndahimana Jd,Kayirangwa E,Dahourou AG,Balisanga H,DeVos JR,McAlister D,Yang C,Bertagnolio S,Riedel DJ,Nsanzimana S

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

journal_title：Antiviral therapy

authors： Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...

journal_title：Antiviral therapy

authors： Parker S,Schriewer J,Oberle C,Robertson A,Lanier R,Painter G,Buller RM

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:A significant proportion of hepatitis C patients treated with unmodified interferon plus ribavirin fail to respond. The optimal therapy for these patients has not been established yet. The objective of this study was to assess the efficacy and safety of peginterferon plus ribavirin with or without amantidine...

journal_title：Antiviral therapy

authors： Hasan F,Al-Khaldi J,Asker H,Al-Ajmi M,Owayed S,Varghese R,Siddique I,Al-Nakib B

更新日期：2004-08-01 00:00:00

abstract：:The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...

journal_title：Antiviral therapy

authors： Matsumoto K,Ogawa N,Nerome K,Numazaki Y,Kawakami Y,Shirato K,Arakawa M,Kudoh S,Shimokata K,Nakajima S,Yamakido M,Kashiwagi S,Nagatake T

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A c...

journal_title：Antiviral therapy

authors： Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

更新日期：2009-01-01 00:00:00

abstract：:In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cells during sexual transmission. The compounds tested included the secon...

journal_title：Antiviral therapy

authors： Njai HF,Lewi PJ,Janssen CG,Garcia S,Fransen K,Kestens L,Vanham G,Janssen PA

更新日期：2005-01-01 00:00:00

abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

journal_title：Antiviral therapy

authors： Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

journal_title：Antiviral therapy

authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

journal_title：Antiviral therapy

authors： Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...

journal_title：Antiviral therapy

authors： Yazdanpanah Y,Goldie SJ,Losina E,Weinstein MC,Lebrun T,Paltiel AD,Seage GR 3rd,Leblanc G,Ajana F,Kimmel AD,Zhang H,Salamon R,Mouton Y,Freedberg KA

更新日期：2002-12-01 00:00:00

abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

journal_title：Antiviral therapy

authors： Xie X,Jiang Y,Zeng Y,Liu H

更新日期：2020-06-04 00:00:00

abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

journal_title：Antiviral therapy

authors： European Collaborative Study.

更新日期：2010-01-01 00:00:00

abstract：:In 1998 it seems reasonable and widely accepted that all human immunodeficiency virus type 1 (HIV-1)-infected patients willing to be treated may benefit from receiving antiretroviral therapy. Only those with undetectable plasma HIV-1 RNA, normal CD4 lymphocyte counts and lack of markers of immunological system activat...

journal_title：Antiviral therapy

authors： Gatell JM

更新日期：1998-01-01 00:00:00

abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

journal_title：Antiviral therapy

authors： Kim BK,Revill PA,Ahn SH

更新日期：2011-01-01 00:00:00

abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

journal_title：Antiviral therapy

authors： Fung SK,Lok AS

更新日期：2004-12-01 00:00:00

abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

journal_title：Antiviral therapy

authors： Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...

journal_title：Antiviral therapy

authors： Huang YW,Hu JT,Hu FC,Chang CJ,Chang HY,Kao JH,Yang SS,Chen DS

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS:Two different real-time PCR platforms, the CO...

journal_title：Antiviral therapy

authors： Taylor N,Haschke-Becher E,Greil R,Strasser M,Oberkofler H

更新日期：2014-01-01 00:00:00